Key Points
- Board approves arrangement to manufacture and market Viagra locally
- Disclosure made through official notice to Pakistan Stock Exchange
- AGP to act as contract manufacturer and marketing partner
- Product launch expected in May 2026, subject to formalities
ISLAMABAD: AGP Limited has announced plans to manufacture and market the globally known erectile dysfunction drug Viagra in Pakistan, following approval by its board of directors and formal disclosure to the Pakistan Stock Exchange.
According to the company’s official notice submitted to the exchange, the board, in its meeting held on April 29, 2026, approved entering into an arrangement with an associated company under which AGP will undertake contract manufacturing and marketing of the product.
“The Board of Directors… approved the entering into an arrangement… under which the company shall undertake contract manufacturing and marketing services for the pharmaceutical product ‘Viagra’,” the filing stated.
Under the proposed structure, AGP will act as the contract manufacturing organisation for Viagra and will also hold marketing rights, allowing it to commercialise and promote the product in Pakistan.
The company added that necessary agreements between the parties are currently being finalised, with the product expected to be launched in May 2026, subject to completion of regulatory and operational formalities.
The development reflects AGP’s strategy of expanding its portfolio through licensed products and partnerships with international pharmaceutical firms.
The company operates across manufacturing, marketing, and distribution of pharmaceutical products, with an established nationwide network.
Market participants view the move as significant for Pakistan’s healthcare sector, as local manufacturing of such products could improve availability and potentially reduce reliance on imported alternatives, particularly in a high-demand therapeutic category.
